NO20035139D0 - Karbocykliske hydrazininhibitorer for kobber inneholdende aminoksydaser - Google Patents
Karbocykliske hydrazininhibitorer for kobber inneholdende aminoksydaserInfo
- Publication number
- NO20035139D0 NO20035139D0 NO20035139A NO20035139A NO20035139D0 NO 20035139 D0 NO20035139 D0 NO 20035139D0 NO 20035139 A NO20035139 A NO 20035139A NO 20035139 A NO20035139 A NO 20035139A NO 20035139 D0 NO20035139 D0 NO 20035139D0
- Authority
- NO
- Norway
- Prior art keywords
- diseases
- sup
- inhibitors
- amine oxidases
- ssao
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C243/00—Compounds containing chains of nitrogen atoms singly-bound to each other, e.g. hydrazines, triazanes
- C07C243/24—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids
- C07C243/26—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids with acylating carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C243/28—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids with acylating carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of a saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C243/00—Compounds containing chains of nitrogen atoms singly-bound to each other, e.g. hydrazines, triazanes
- C07C243/10—Hydrazines
- C07C243/20—Hydrazines having nitrogen atoms of hydrazine groups bound to carbon atoms of rings other than six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/902,789 US6982286B2 (en) | 2001-07-12 | 2001-07-12 | Carbocyclic hydrazino inhibitors of copper-containing amine oxidases |
PCT/FI2002/000630 WO2003006003A1 (en) | 2001-07-12 | 2002-07-11 | Carbocyclic hydrazino inhibitors of copper-containing amine oxidases |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20035139D0 true NO20035139D0 (no) | 2003-11-19 |
Family
ID=25416395
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20035139A NO20035139D0 (no) | 2001-07-12 | 2003-11-19 | Karbocykliske hydrazininhibitorer for kobber inneholdende aminoksydaser |
Country Status (15)
Country | Link |
---|---|
US (2) | US6982286B2 (ja) |
EP (1) | EP1414426B1 (ja) |
JP (1) | JP4377221B2 (ja) |
KR (1) | KR20040017289A (ja) |
CN (1) | CN1520290A (ja) |
AT (1) | ATE318589T1 (ja) |
CA (1) | CA2451569A1 (ja) |
DE (1) | DE60209504T2 (ja) |
ES (1) | ES2259379T3 (ja) |
HU (1) | HUP0401097A3 (ja) |
IL (1) | IL159205A0 (ja) |
NO (1) | NO20035139D0 (ja) |
RU (1) | RU2004103869A (ja) |
WO (1) | WO2003006003A1 (ja) |
ZA (1) | ZA200309112B (ja) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6982286B2 (en) * | 2001-07-12 | 2006-01-03 | Biotie Therapies Corp. | Carbocyclic hydrazino inhibitors of copper-containing amine oxidases |
FI20022007A0 (fi) * | 2002-11-08 | 2002-11-08 | Juvantia Pharma Ltd Oy | Oromukosaalinen valmiste ja menetelmä sen valmistamiseksi |
US7125901B2 (en) * | 2003-01-27 | 2006-10-24 | Astellas Pharma Inc. | Thiazole derivatives |
WO2004087138A1 (en) * | 2003-03-31 | 2004-10-14 | Sucampo Ag | Method for treating vascular hyperpermeable disease |
DK1633861T3 (da) * | 2003-05-26 | 2010-03-22 | Biotie Therapies Corp | Krystallinsk VAP-1 og anvendelser deraf |
FI20031927A0 (fi) * | 2003-12-31 | 2003-12-31 | Faron Pharmaceuticals Oy | Terapeuttisesti vaikuttavia aineita ja niiden käyttö |
FI20040136A0 (fi) * | 2004-01-30 | 2004-01-30 | Faron Pharmaceuticals Oy | Erityisesti diabeetikoille soveltuvia koostumuksia |
US8119651B2 (en) * | 2004-01-30 | 2012-02-21 | Biotie Therapies Corp. | Compositions useful especially for treatment or prevention of metabolic syndrome |
DK1708711T3 (da) * | 2004-01-30 | 2010-06-14 | Biotie Therapies Oyj | Sammensætninger, der især er anvendelige til behandling eller forebyggelse af metabolisk syndrom |
JP4140630B2 (ja) * | 2005-11-10 | 2008-08-27 | Tdk株式会社 | 磁気ヘッドアセンブリ及び磁気ヘッドアセンブリの製造方法 |
US8636995B2 (en) * | 2006-08-31 | 2014-01-28 | Cardiac Pacemakers, Inc. | Methods and devices to regulate stem cell homing |
US20080058922A1 (en) * | 2006-08-31 | 2008-03-06 | Cardiac Pacemakers, Inc. | Methods and devices employing vap-1 inhibitors |
US8372399B2 (en) | 2006-08-31 | 2013-02-12 | Cardiac Pacemakers, Inc. | Bispecific antibodies and agents to enhance stem cell homing |
US20080207728A1 (en) * | 2006-12-15 | 2008-08-28 | Lars Wortmann | Bicyclic acyltryptophanols |
US20090170770A1 (en) * | 2007-11-06 | 2009-07-02 | Ali Hafezi-Moghadam | Methods and compositions for treating conditions associated with angiogenesis using a vascular adhesion protein-1 (vap 1) inhibitor |
US8906642B2 (en) | 2008-09-03 | 2014-12-09 | Universitat Autonoma De Barcelona | Methods and compositions for the treatment and diagnosis of haemorrhagic conversion |
WO2010033045A1 (en) * | 2008-09-16 | 2010-03-25 | Igor Anatolievich Pomytkin | Compositions and methods for prevention or treatment of beta amyloid deposition |
JP2012510983A (ja) | 2008-12-04 | 2012-05-17 | プロキシマジェン エルティーディー | イミダゾピリジン化合物 |
UA112154C2 (uk) | 2009-09-08 | 2016-08-10 | Біоті Терапіс Корп. | Застосування повністю людського анти-vap-1-антитіла для лікування фіброзних станів |
GB201004311D0 (en) | 2010-03-15 | 2010-04-28 | Proximagen Ltd | New enzyme inhibitor compounds |
FI20115234A0 (fi) | 2011-03-08 | 2011-03-08 | Biotie Therapies Corp | Uusia pyridatsinoni- ja pyridoniyhdisteitä |
GB201115853D0 (en) | 2011-09-14 | 2011-10-26 | Proximagen Ltd | New enzyme inhibitor compounds |
JP5796130B2 (ja) | 2011-09-14 | 2015-10-21 | プロクシマゲン リミテッド | 新規な酵素阻害剤化合物 |
GB201304527D0 (en) | 2013-03-13 | 2013-04-24 | Proximagen Ltd | New compounds |
GB201304526D0 (en) | 2013-03-13 | 2013-04-24 | Proximagen Ltd | New compounds |
US20160113893A1 (en) | 2013-06-12 | 2016-04-28 | Proximagen Limited | New therapeutic uses of enzyme inhibitors |
ES2714125T3 (es) | 2014-04-15 | 2019-05-27 | Pecsi Tudomanyegyetem | Inhibidores de la amino oxidasa sensible a la semicarbazida para uso como analgésicos en una neuropatía traumática y una inflamación neurogénica |
WO2015189534A1 (en) | 2014-06-12 | 2015-12-17 | Proximagen Limited | Vap-1 inhibitors for treating muscular dystrophy |
GB201416446D0 (en) | 2014-09-17 | 2014-10-29 | Proximagen Ltd | New enzyme inhibitor compounds |
GB201416444D0 (en) | 2014-09-17 | 2014-10-29 | Proximagen Ltd | New compounds |
CA3007768A1 (en) | 2015-12-07 | 2017-06-15 | Benevolentai Cambridge Limited | Vap-1 inhibitors for treating pain |
GB201521541D0 (en) * | 2015-12-07 | 2016-01-20 | Proximagen Ltd | New therapeutic uses of enzyme inhibitors |
GB201709136D0 (en) * | 2017-06-08 | 2017-07-26 | Proximagen Ltd | New therapeutic uses of enzyme inhibitors |
CN109988147A (zh) * | 2017-12-29 | 2019-07-09 | 佛山汉方中医医院有限公司 | 含金刚烷结构的ssao抑制剂、制备方法及其用途 |
CN108191824A (zh) * | 2017-12-29 | 2018-06-22 | 佛山汉方中医医院有限公司 | 一种甲基金刚烷和二甲胺吡啶结构衍生物、其制备方法及其用途 |
CN107915719A (zh) * | 2017-12-29 | 2018-04-17 | 佛山汉方中医医院有限公司 | 一类甲基金刚烷和吡啶结构的ssao抑制剂及其用途 |
CN107935990A (zh) * | 2017-12-29 | 2018-04-20 | 佛山汉方中医医院有限公司 | 含金刚烷和烷氧吡啶结构化合物、其制备方法及用途 |
CN108033945A (zh) * | 2017-12-29 | 2018-05-15 | 佛山汉方中医医院有限公司 | 一种金刚烷和硝基吡啶结构化合物及用途 |
CN107935989A (zh) * | 2017-12-29 | 2018-04-20 | 佛山汉方中医医院有限公司 | 金刚烷和腈基吡啶结构化合物、其制备方法及用途 |
CN108129458A (zh) * | 2017-12-29 | 2018-06-08 | 佛山汉方中医医院有限公司 | 一种金刚烷和二甲胺吡啶结构衍生物、其制备方法及用途 |
CN108084154A (zh) * | 2017-12-29 | 2018-05-29 | 佛山汉方中医医院有限公司 | 一种金刚烷和胺基吡啶结构衍生物、其制备方法及用途 |
CN108191823A (zh) * | 2017-12-29 | 2018-06-22 | 佛山汉方中医医院有限公司 | 一类烷基取代金刚烷ssao抑制剂、制备方法及其用途 |
CN107935993A (zh) * | 2017-12-29 | 2018-04-20 | 佛山汉方中医医院有限公司 | 甲基金刚烷和硝基吡啶结构衍生物、其制备方法及其用途 |
CN108084155A (zh) * | 2017-12-29 | 2018-05-29 | 佛山汉方中医医院有限公司 | 甲基金刚烷和烷氧吡啶结构的ssao抑制剂及其用途 |
CN108033946A (zh) * | 2017-12-29 | 2018-05-15 | 佛山汉方中医医院有限公司 | 一种含金刚烷结构的ssao抑制剂、制备方法及其用途 |
CN107935992A (zh) * | 2017-12-29 | 2018-04-20 | 佛山汉方中医医院有限公司 | 一类含金刚烷和卤代吡啶结构化合物及用途 |
CN108191825A (zh) * | 2017-12-29 | 2018-06-22 | 佛山汉方中医医院有限公司 | 一种甲基金刚烷和硝基吡啶结构衍生物及其用途 |
SE544131C2 (en) * | 2020-03-16 | 2022-01-04 | Pvac Medical Tech Ltd | Use of substance and pharmaceutical composition thereof, and medical treatments or uses thereof |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3105849A (en) | 1960-02-01 | 1963-10-01 | Ciba Geigy Corp | Bicyclic hydrazinium compounds |
WO1998055439A1 (en) | 1997-06-05 | 1998-12-10 | Venantius Limited | Indane compounds and their pharmaceutical use |
WO1998055447A1 (en) | 1997-06-05 | 1998-12-10 | Venantius Limited | 3-aminoindane derivatives, process for their preparation and pharmaceutical compositions containing them |
AU2001282162A1 (en) | 2000-07-05 | 2002-01-14 | Biotie Therapies Corp. | Inhibitors of copper-containing amine oxidases |
US6982286B2 (en) * | 2001-07-12 | 2006-01-03 | Biotie Therapies Corp. | Carbocyclic hydrazino inhibitors of copper-containing amine oxidases |
-
2001
- 2001-07-12 US US09/902,789 patent/US6982286B2/en not_active Expired - Fee Related
-
2002
- 2002-07-11 ES ES02751224T patent/ES2259379T3/es not_active Expired - Lifetime
- 2002-07-11 WO PCT/FI2002/000630 patent/WO2003006003A1/en active IP Right Grant
- 2002-07-11 KR KR10-2004-7000368A patent/KR20040017289A/ko not_active Application Discontinuation
- 2002-07-11 IL IL15920502A patent/IL159205A0/xx unknown
- 2002-07-11 EP EP02751224A patent/EP1414426B1/en not_active Expired - Lifetime
- 2002-07-11 US US10/483,291 patent/US20040236108A1/en not_active Abandoned
- 2002-07-11 DE DE60209504T patent/DE60209504T2/de not_active Expired - Lifetime
- 2002-07-11 RU RU2004103869/04A patent/RU2004103869A/ru not_active Application Discontinuation
- 2002-07-11 AT AT02751224T patent/ATE318589T1/de not_active IP Right Cessation
- 2002-07-11 CN CNA028128915A patent/CN1520290A/zh active Pending
- 2002-07-11 JP JP2003511809A patent/JP4377221B2/ja not_active Expired - Fee Related
- 2002-07-11 HU HU0401097A patent/HUP0401097A3/hu unknown
- 2002-07-11 CA CA002451569A patent/CA2451569A1/en not_active Abandoned
-
2003
- 2003-11-19 NO NO20035139A patent/NO20035139D0/no not_active Application Discontinuation
- 2003-11-24 ZA ZA200309112A patent/ZA200309112B/en unknown
Also Published As
Publication number | Publication date |
---|---|
US20040236108A1 (en) | 2004-11-25 |
US20030125360A1 (en) | 2003-07-03 |
CN1520290A (zh) | 2004-08-11 |
RU2004103869A (ru) | 2005-03-27 |
IL159205A0 (en) | 2004-06-01 |
HUP0401097A2 (hu) | 2004-09-28 |
ES2259379T3 (es) | 2006-10-01 |
EP1414426A1 (en) | 2004-05-06 |
US6982286B2 (en) | 2006-01-03 |
DE60209504D1 (de) | 2006-04-27 |
WO2003006003A1 (en) | 2003-01-23 |
KR20040017289A (ko) | 2004-02-26 |
DE60209504T2 (de) | 2006-10-12 |
CA2451569A1 (en) | 2003-01-23 |
HUP0401097A3 (en) | 2006-02-28 |
ZA200309112B (en) | 2004-07-23 |
JP4377221B2 (ja) | 2009-12-02 |
JP2005501035A (ja) | 2005-01-13 |
EP1414426B1 (en) | 2006-03-01 |
ATE318589T1 (de) | 2006-03-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20035139D0 (no) | Karbocykliske hydrazininhibitorer for kobber inneholdende aminoksydaser | |
WO2002002090A3 (en) | Inhibitors of copper-containing amine oxidases | |
MXPA05010958A (es) | Derivados indazol como inhibidores jnk. | |
BRPI0509282A (pt) | compostos contendo hidrazida inibidores de cftr e seus usos | |
NO20050851L (no) | Kaspase-inhibitorer og anvendelser derav | |
HRP20050967A2 (en) | Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors | |
TW200614983A (en) | 5-substituted-2-phenylamino benzamides as MEK inhibitors | |
EP1592665A4 (en) | HISTONE DEACETYLASE INHIBITORS OF NEW POWERFUL DIFFERENTIATION BENZAMIDE DERIVATIVES WITH PROLIFERATION-INHIBITING ACTIVITY | |
WO2005030083A3 (en) | Methods and products which utilize n-acyl-l-aspartic acid | |
EP1562897A4 (en) | PHENYL ACARBOXAMIDE AS A BETA SEKRETASE INHIBITOR FOR THE TREATMENT OF ALZHEIMER | |
MXPA05008172A (es) | Derivados de malonamida como inhibidores gamma-secretasa. | |
MY127898A (en) | Dual-release compositions of a cyclooxygenase-2 inhibitor | |
GB0112348D0 (en) | Compounds | |
EA200601418A1 (ru) | ПРОИЗВОДНЫЕ 1Н-ТИЕНО [2,3-с] ПИРАЗОЛА, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ ИСПОЛЬЗОВАНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ КИНАЗЫ | |
HK1062633A1 (en) | Azoles as malonyl-coa decarboxylase inhibitors useful as metabolic modulators | |
EE05423B1 (et) | IL-18 inhibiitori kasutamine maksakahjustuse ja muude haiguste raviks v?i ennetamiseks sobiva ravimi valmistamiseks, vektori ja raku kasutamine inhibiitori produtseerimisel ning IL-18 inhibiitorit sisaldav farmatseutiline kompositsioon | |
WO2007075572A3 (en) | Orally active purine-based inhibitors of heat shock protein 90 | |
MX2022012310A (es) | Metodos para tratar la esclerosis multiple recidivante con un inhibidor de tirosina quinasa de bruton. | |
Flinn et al. | Evidence of Clinical Activity in a Phase 1 Study of CAL-101, An Oral P110Δ Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase, in Patients with Relapsed or Refractory B-Cell Malignancies. | |
WO2004100893A3 (en) | Methods for treatment of inflammatory diseases using ct-3 or analogs thereof | |
CL2023000296A1 (es) | Uso de dexpramipexol para el tratamiento del asma moderado a grave | |
EP1695969A4 (en) | ALPHA-AMINO-ACID DERIVATIVES AND THEIR USE AS MEDICINE | |
TW200505916A (en) | 7-azaindoles and the use thereof as therapeutic agents | |
CA2489705A1 (en) | Use of amide derivative of ge 2270 factor a3 for the treatment of acne | |
TW200505448A (en) | 5-hydroxyindoles with n-oxide groups and the use thereof as therapeutic agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |